Prof Dr Ed Schuuring, PhD, senior clinical scientist in molecular pathology, University Medical Center Groningen, Groningen, The Netherlands
Three decades his research focuses on the identification of prognostic/predictive epigenetic and molecular markers for clinical outcome, response to chemo-radiotherapy, gene-targeted therapy and treatment-resistance in lung, GIST, head&neck cancer, as well as the early detection of cervical cancer in scrapings. His latest research interest is the implementation of the detection and monitoring of circulating tumor DNA from blood plasma as a bloodborne-based molecular tool to predict of tumor response and resistance to TKI-treatment in GIST and to immunotherapy in NSCLC using mutation testing by digital droplet PCR, MassArray and innovative NGS approaches. He is heading the laboratory of Molecular Pathology offering the latest innovative methods for treatment-decision-making in the region North-Netherlands. Since 1997 he is active in (inter)national committees and advisory boards on implementing Molecular Pathology, the organisation of international proficiency mutation testing in lung tissue biopsies and plasma ctDNA, and co-authored various international guidelines on Molecular Pathology. He graduated in Medical Biology in 1985 and PhD in 1993 in Molecular Biology (University of Amsterdam). He worked as a staff clinical scientist in Molecular Pathology at LUMC (1991-2000) and UMCG (2001-now). He acts as a principal investigator for several postdoctoral, clinical and PhD-student projects, and is co-author on >230 peer-reviewed papers.
Please find more details on my research and publications on http://www.rug.nl/staff/e.m.d.schuuring/ and information on Molecular Pathology on www.moloncopath.nl and www.pathology.nl